🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with Washington are "built on sand." This follows revelations that a so-called "milestone" deal on pharmaceutical tariffs, which pledges zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond limited headline terms contained within government press releases.

A Deal Without Detail

The US-UK pharmaceuticals agreement, described as a "generational" achievement, remains an "statement of intent" without formal ratification. It has been highlighted that the public statements from the UK and US governments present the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement highlights the commitment for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has promised concessions to increase medicine costs in return for only a verbal promise from President Trump," commented David Henig, a trade expert. "It is documented he has a tendency for not keeping promises."

A Pattern of Unreliability

Anxieties have been amplified by Washington's action to put on ice the major technology agreement, which was previously heralded as "a huge leap forward" in the bilateral relationship. The US pointed to a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an May trade agreement have not been formally ratified by the US, despite a imminent January deadline. "It is our belief that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

In confidential discussions, ministers have expressed concerns that the government's deals with Washington are flimsy and unreliable. One minister described the series of agreements as "built on sand," while another described the situation as the "current reality" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, a senior MP on the health committee, argued: "Perhaps most shocking than the administration's tactics is the UK government's credulous faith that his administration is a trustworthy negotiator. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Officials have sought to reduce the risk of the US withdrawing from the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials acknowledge that unpredictability is part and parcel of dealing with the Trump administration. However, they contend that the UK has obtained tangible results for businesses, such as lower steel tariffs compared to other nations. "Securing 25% steel tariffs, which is better than the rate for the rest of the world, is not flimsy," one official said.

Yet, delays have emerged in carrying out the initial US-UK accord. Promised access for British beef have not materialized, and the pledge to "eliminate duties on UK metals" has not been fulfilled, with tariffs fixed at 25%.

Moving forward, the two sides have planned to recommence talks on the suspended digital agreement in January, following what were described as "productive" meetings between UK and US officials in Washington.